Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.
Molderings GJ, Dumoulin FL, Homann J, Sido B, Textor J, Mücke M, Qagish GJ, Barion R, Raithel M, Klingmüller D, Schäfer VS, Hertfelder HJ, Berdel D, Tridente G, Weinstock LB, Afrin LB.
Molderings GJ, et al. Among authors: raithel m.
Naunyn Schmiedebergs Arch Pharmacol. 2020 Sep;393(9):1573-1580. doi: 10.1007/s00210-020-01886-2. Epub 2020 May 6.
Naunyn Schmiedebergs Arch Pharmacol. 2020.
PMID: 32377770
Free PMC article.
Review.